Paper · 36083147

FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer.

Gonzalez-Ericsson PI and 6 others. Appl Immunohistochem Mol Morphol, 2022. Cited by 5 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer. Papers, record 36083147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36083147

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer.; PubMed
Journal: Appl Immunohistochem Mol Morphol; PubMed
Year: 2022; PubMed
Publication types: Journal Article, Research Support, N.I.H., Extramural; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/36083147/; PubMed
DOI: https://doi.org/10.1097/pai.0000000000001058; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9547979/; PubMed
The journal: https://conductscience.org/library/journal-index/100888796; PubMed
Citations, by iCite: 5; iCite
Relative citation ratio, by iCite: 0.29; iCite
Revised in PubMed: 2023-10-02; PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Gonzalez-Ericsson PI	Paula I	https://orcid.org/0000-0002-6292-6963
2	Servetto A	Alberto
3	Formisano L	Luigi
4	Sánchez V	Violeta
5	Mayer IA	Ingrid A
6	Arteaga CL	Carlos L
7	Sanders ME	Melinda E

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Breast Neoplasms	Major topic
Receptor, Fibroblast Growth Factor, Type 1	Major topic
Female
Gene Amplification
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Protein Kinase Inhibitors

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
P50 CA098131	NCI NIH HHS	United States	P50CA098131	PubMed and NIH

Source NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMID	Title	Journal	Year	In Papers	Source
42,713,707	Differential FGFR1 copy number status displays unique tumour immune microenvironment in triple-negative breast cancer.	J Pathol	2026	https://conductscience.org/library/papers/42713707	PubMed
40,627,530	Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer.	Clin Cancer Res	2025	https://conductscience.org/library/papers/40627530	PubMed
40,127,812	Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.	Cancer Lett	2025	https://conductscience.org/library/papers/40127812	PubMed
37,750,089	FGFR families: biological functions and therapeutic interventions in tumors.	MedComm (2020)	2023	https://conductscience.org/library/papers/37750089	PubMed
37,546,410	FGF/FGFR1 system in paired breast tumor-adjacent and tumor tissues, associations with mammographic breast density and tumor characteristics.	Front Oncol	2023	https://conductscience.org/library/papers/37546410	PubMed

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
CYP19A1	1,588	PubTator's text mining	https://conductscience.org/library/genes/1588	NCBI Gene
ERBB2	2,064	PubTator's text mining	https://conductscience.org/library/genes/2064	NCBI Gene
EREG	2,069	PubTator's text mining	https://conductscience.org/library/genes/2069	NCBI Gene
FGFR1	2,260	PubTator's text mining	https://conductscience.org/library/genes/2260	NCBI Gene
LSM1	27,257	PubTator's text mining	https://conductscience.org/library/genes/27257	NCBI Gene
NR4A1	3,164	PubTator's text mining	https://conductscience.org/library/genes/3164	NCBI Gene
NSD3	54,904	PubTator's text mining	https://conductscience.org/library/genes/54904	NCBI Gene
TXK	7,294	PubTator's text mining	https://conductscience.org/library/genes/7294	NCBI Gene
ZNF703	80,139	PubTator's text mining	https://conductscience.org/library/genes/80139	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36083147

GET https://conductscience.org/api/papers/v1/36083147/authors

API reference For AI assistants